<p>Hims
&amp; Hers Health, Inc. (NYSE:HIMS - 获取免费报告) 周五下跌了 0.9%。该股最低交易价为 33.22 美元，最后交易价为 34.07 美元。在交易中，共成交了 7,643,464 股，较平均交易量 13,064,865 股下降了 41%。该股此前收盘价为 34.39 美元。</p>
<p>获取 <strong>Hims &amp; Hers Health</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<ul>
<li>错过了 Hims &amp; Hers 的上涨？Clover Health 可能是下一个</li>
</ul>
<p>HIMS 最近成为几份研究报告的主题。花旗集团在周四的报告中重申了对 Hims &amp; Hers Health 的 &#34;卖出&#34; 评级，并设定了 27.00 美元的目标价。Canaccord Genuity Group 在 2 月 19 日的报告中将 Hims &amp; Hers Health 的目标价从 38.00 美元上调至 68.00 美元，并给予该股 &#34;买入&#34; 评级。摩根士丹利在 2 月 18 日的研究报告中将 Hims &amp; Hers Health 的评级从 &#34;超配&#34; 下调至 &#34;同等权重&#34;，并将该股的目标价从 42.00 美元上调至 60.00 美元。BTIG Research 在 1 月 7 日的研究报告中开始覆盖 Hims &amp; Hers Health 的股票。他们给予该公司 &#34;买入&#34; 评级，并设定了 35.00 美元的目标价。最后，Leerink Partners 在 2 月 25 日的研究报告中将 Hims &amp; Hers Health 的目标价从 24.00 美元上调至 40.00 美元，并给予该股 &#34;市场表现&#34; 评级。两位股票研究分析师对该股给予了卖出评级，七位给予了持有评级，六位给予了买入评级。根据 MarketBeat.com 的数据，Hims &amp; Hers Health 目前的平均评级为 &#34;持有&#34;，平均目标价为 37.23 美元。</p>
<p><strong>阅读我们对 HIMS 的最新股票分析</strong></p>
<h2>Hims &amp; Hers Health 股票表现</h2>
<ul>
<li>华尔街最受关注：目前的两只高度被做空的股票</li>
</ul>
<p>该公司的市值为 79.7 亿美元，市盈率为 81.33，贝塔值为 1.37。该公司的 50 日移动平均价格为 37.45 美元，200 日移动平均价格为 27.31 美元。</p>
<p>Hims &amp; Hers Health (NYSE:HIMS - 获取免费报告) 最近于 2 月 24 日发布了季度财报。该公司报告每股收益（EPS）为 0.11 美元，超出分析师一致预期的 0.09 美元，超出幅度为 0.02 美元。Hims &amp; Hers Health 的净利润率为 8.19%，股本回报率为 10.97%。该公司季度收入为 4.8114 亿美元，而一致预期为 4.9456 亿美元。平均而言，股票分析师预测 Hims &amp; Hers Health, Inc. 本年度每股收益将为 0.29 美元。</p>
<h2>内部交易活动</h2>
<ul>
<li>MarketBeat 周回顾 – 02/17 - 02/21</li>
</ul>
<p>在其他消息中，内部人士 Soleil Boughton 于 2 月 18 日出售了 4,152 股该公司的股票。该股票以平均价格 60.69 美元出售，总交易额为 251,984.88 美元。交易后，该内部人士现在直接持有 157,345 股公司股票，价值约为 9,549,268.05 美元。这笔交易代表了他们持股的 2.57% 的减少。该出售在与 SEC 的法律文件中披露，可以通过此链接访问。此外，内部人士 Michael Chi 于 12 月 10 日出售了 7,259 股 Hims &amp; Hers Health 股票。该股票以平均价格 32.25 美元出售，总价值为 234,102.75 美元。出售后，该内部人士现在直接持有 184,947 股公司股票，价值约为 5,964,540.75 美元。这笔交易代表了他们持股的 3.78% 的减少。该出售的披露可以在这里找到。在过去的一个季度中，内部人士共出售了 1,062,011 股公司股票，价值为 36,892,724 美元。当前 17.71% 的股票由公司内部人士持有。</p>
<h2>Hims &amp; Hers Health 的机构交易</h2>
<p>机构投资者和对冲基金最近对该公司的持仓进行了调整。Creative Planning 在第三季度将其在 Hims &amp; Hers Health 的持仓增加了 18.1%。Creative Planning 目前持有 25,925 股公司股票，价值 478,000 美元，在此期间又购买了 3,979 股。Robeco Institutional Asset Management B.V. 在第三季度购买了 Hims &amp; Hers Health 的新头寸，价值约为 604,000 美元。QRG Capital Management Inc. 在第三季度将其在 Hims &amp; Hers Health 的持仓增加了 3.9%。QRG Capital Management Inc. 目前持有 162,029 股公司股票，价值 2,985,000 美元，在此期间又购买了 6,077 股。Olympiad Research LP 在第三季度购买了 Hims &amp; Hers Health 的新头寸，价值约为 262,000 美元。最后，Principal Financial Group Inc. 在第三季度将其在 Hims &amp; Hers Health 的持仓增加了 102.0%。Principal Financial Group Inc. 目前持有 290,414 股公司股票，价值 5,349,000 美元，在此期间又购买了 146,621 股。当前 63.52% 的股票由机构投资者持有。</p>
<h2>关于 Hims &amp; Hers Health</h2>
<p>(获取免费报告)</p>
<p>Hims &amp; Hers Health, Inc. 运营一个远程医疗咨询平台。它将消费者与医疗专业人员连接，使他们能够获得心理健康、性健康、皮肤病和初级护理的医疗服务。该公司成立于 2017 年，总部位于加利福尼亚州旧金山。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过 Hims &amp; Hers Health</li>
<li>特殊目的收购公司 (SPAC) 你需要知道的事项</li>
<li>Myers Industries 是否准备突破？</li>
<li>低市盈率增长股票：解锁投资机会</li>
<li>BigBear.ai 的 25% 暴跌是虚惊一场还是火灾销售？</li>
<li>股票市场升级：它们是什么？</li>
<li>Broadcom 确认其人工智能前景：股票即将创下新高</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Hims &amp; Hers Health 吗？</h2>
<p>在考虑 Hims &amp; Hers Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Hims &amp; Hers Health 并不在名单上。</p>
<p>虽然 Hims &amp; Hers Health 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

HIMS

<p>Hims & Hers Health（纽约证券交易所代码：HIMS）股价下跌 0.9%，至 34.07 美元，交易量较平均水平下降 41%。分析师的评级不一，花旗集团维持 27 美元的 “卖出” 评级，而 Canaccord Genuity 将目标价上调至 68 美元，并给予 “买入” 评级。该公司报告第四季度每股收益为 0.11 美元，超出预期，但营收为 4.8114 亿美元，未达到预期。内部交易活动包括 Soleil Boughton 和 Michael Chi 的股票出售，内部人士持有 17.71% 的股份。Hims & Hers 的市值为 79.7 亿美元，平均目标价为 37.23 美元</p>

<p>Hims &amp; Hers Health, Inc. (NYSE:HIMS - Get Free Report) traded down 0.9% on Friday . The stock traded as low as $33.22 and last traded at $34.07. 7,643,464 shares changed hands during trading, a decline of 41% from the average session volume of 13,064,865 shares. The stock had previously closed at $34.39.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health, Inc. (NYSE:HIMS - 获取免费报告) 周五下跌了 0.9%。该股最低交易价为 33.22 美元，最后交易价为 34.07 美元。在交易中，共成交了 7,643,464 股，较平均交易量 13,064,865 股下降了 41%。该股此前收盘价为 34.39 美元。</p>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Hims &amp; Hers Health</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>Missed the Hims &amp; Hers Rally? Clover Health Could Be Next</li>
</ul>
<div class="lb-trans"><ul>
<li>错过了 Hims &amp; Hers 的上涨？Clover Health 可能是下一个</li>
</ul>
</div><p>HIMS has been the subject of several recent research reports. Citigroup reissued a &#34;sell&#34; rating and set a $27.00 price target on shares of Hims &amp; Hers Health in a report on Thursday. Canaccord Genuity Group increased their target price on shares of Hims &amp; Hers Health from $38.00 to $68.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, February 19th. Morgan Stanley cut shares of Hims &amp; Hers Health from an &#34;overweight&#34; rating to an &#34;equal weight&#34; rating and raised their target price for the stock from $42.00 to $60.00 in a research note on Tuesday, February 18th. BTIG Research initiated coverage on shares of Hims &amp; Hers Health in a research report on Tuesday, January 7th. They issued a &#34;buy&#34; rating and a $35.00 price target for the company. Finally, Leerink Partners increased their price objective on shares of Hims &amp; Hers Health from $24.00 to $40.00 and gave the stock a &#34;market perform&#34; rating in a research note on Tuesday, February 25th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Hims &amp; Hers Health presently has an average rating of &#34;Hold&#34; and an average target price of $37.23.</p>
<div class="lb-trans"><p>HIMS 最近成为几份研究报告的主题。花旗集团在周四的报告中重申了对 Hims &amp; Hers Health 的 &#34;卖出&#34; 评级，并设定了 27.00 美元的目标价。Canaccord Genuity Group 在 2 月 19 日的报告中将 Hims &amp; Hers Health 的目标价从 38.00 美元上调至 68.00 美元，并给予该股 &#34;买入&#34; 评级。摩根士丹利在 2 月 18 日的研究报告中将 Hims &amp; Hers Health 的评级从 &#34;超配&#34; 下调至 &#34;同等权重&#34;，并将该股的目标价从 42.00 美元上调至 60.00 美元。BTIG Research 在 1 月 7 日的研究报告中开始覆盖 Hims &amp; Hers Health 的股票。他们给予该公司 &#34;买入&#34; 评级，并设定了 35.00 美元的目标价。最后，Leerink Partners 在 2 月 25 日的研究报告中将 Hims &amp; Hers Health 的目标价从 24.00 美元上调至 40.00 美元，并给予该股 &#34;市场表现&#34; 评级。两位股票研究分析师对该股给予了卖出评级，七位给予了持有评级，六位给予了买入评级。根据 MarketBeat.com 的数据，Hims &amp; Hers Health 目前的平均评级为 &#34;持有&#34;，平均目标价为 37.23 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on HIMS</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 HIMS 的最新股票分析</strong></p>
</div><h2>Hims &amp; Hers Health Stock Performance</h2>
<div class="lb-trans"><h2>Hims &amp; Hers Health 股票表现</h2>
</div><ul>
<li>Wall Street’s Most Wanted: 2 Highly Shorted Stocks Right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>华尔街最受关注：目前的两只高度被做空的股票</li>
</ul>
</div><p>The firm has a market capitalization of $7.97 billion, a PE ratio of 81.33 and a beta of 1.37. The company has a fifty day moving average price of $37.45 and a 200-day moving average price of $27.31.</p>
<div class="lb-trans"><p>该公司的市值为 79.7 亿美元，市盈率为 81.33，贝塔值为 1.37。该公司的 50 日移动平均价格为 37.45 美元，200 日移动平均价格为 27.31 美元。</p>
</div><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. Hims &amp; Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. On average, equities analysts predict that Hims &amp; Hers Health, Inc. will post 0.29 earnings per share for the current year.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health (NYSE:HIMS - 获取免费报告) 最近于 2 月 24 日发布了季度财报。该公司报告每股收益（EPS）为 0.11 美元，超出分析师一致预期的 0.09 美元，超出幅度为 0.02 美元。Hims &amp; Hers Health 的净利润率为 8.19%，股本回报率为 10.97%。该公司季度收入为 4.8114 亿美元，而一致预期为 4.9456 亿美元。平均而言，股票分析师预测 Hims &amp; Hers Health, Inc. 本年度每股收益将为 0.29 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><ul>
<li>MarketBeat Week in Review – 02/17 - 02/21</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 02/17 - 02/21</li>
</ul>
</div><p>In other news, insider Soleil Boughton sold 4,152 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total transaction of $251,984.88. Following the transaction, the insider now directly owns 157,345 shares of the company's stock, valued at approximately $9,549,268.05. This trade represents a 2.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Michael Chi sold 7,259 shares of Hims &amp; Hers Health stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $32.25, for a total value of $234,102.75. Following the sale, the insider now directly owns 184,947 shares of the company's stock, valued at approximately $5,964,540.75. This trade represents a 3.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,062,011 shares of company stock valued at $36,892,724. 17.71% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他消息中，内部人士 Soleil Boughton 于 2 月 18 日出售了 4,152 股该公司的股票。该股票以平均价格 60.69 美元出售，总交易额为 251,984.88 美元。交易后，该内部人士现在直接持有 157,345 股公司股票，价值约为 9,549,268.05 美元。这笔交易代表了他们持股的 2.57% 的减少。该出售在与 SEC 的法律文件中披露，可以通过此链接访问。此外，内部人士 Michael Chi 于 12 月 10 日出售了 7,259 股 Hims &amp; Hers Health 股票。该股票以平均价格 32.25 美元出售，总价值为 234,102.75 美元。出售后，该内部人士现在直接持有 184,947 股公司股票，价值约为 5,964,540.75 美元。这笔交易代表了他们持股的 3.78% 的减少。该出售的披露可以在这里找到。在过去的一个季度中，内部人士共出售了 1,062,011 股公司股票，价值为 36,892,724 美元。当前 17.71% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Trading of Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>Hims &amp; Hers Health 的机构交易</h2>
</div><p>Institutional investors and hedge funds have recently made changes to their positions in the company. Creative Planning increased its position in Hims &amp; Hers Health by 18.1% during the 3rd quarter. Creative Planning now owns 25,925 shares of the company's stock valued at $478,000 after purchasing an additional 3,979 shares during the period. Robeco Institutional Asset Management B.V. purchased a new position in Hims &amp; Hers Health during the third quarter valued at approximately $604,000. QRG Capital Management Inc. increased its holdings in Hims &amp; Hers Health by 3.9% during the third quarter. QRG Capital Management Inc. now owns 162,029 shares of the company's stock valued at $2,985,000 after buying an additional 6,077 shares during the period. Olympiad Research LP bought a new position in Hims &amp; Hers Health in the third quarter worth approximately $262,000. Finally, Principal Financial Group Inc. lifted its holdings in Hims &amp; Hers Health by 102.0% during the third quarter. Principal Financial Group Inc. now owns 290,414 shares of the company's stock worth $5,349,000 after buying an additional 146,621 shares during the period. 63.52% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近对该公司的持仓进行了调整。Creative Planning 在第三季度将其在 Hims &amp; Hers Health 的持仓增加了 18.1%。Creative Planning 目前持有 25,925 股公司股票，价值 478,000 美元，在此期间又购买了 3,979 股。Robeco Institutional Asset Management B.V. 在第三季度购买了 Hims &amp; Hers Health 的新头寸，价值约为 604,000 美元。QRG Capital Management Inc. 在第三季度将其在 Hims &amp; Hers Health 的持仓增加了 3.9%。QRG Capital Management Inc. 目前持有 162,029 股公司股票，价值 2,985,000 美元，在此期间又购买了 6,077 股。Olympiad Research LP 在第三季度购买了 Hims &amp; Hers Health 的新头寸，价值约为 262,000 美元。最后，Principal Financial Group Inc. 在第三季度将其在 Hims &amp; Hers Health 的持仓增加了 102.0%。Principal Financial Group Inc. 目前持有 290,414 股公司股票，价值 5,349,000 美元，在此期间又购买了 146,621 股。当前 63.52% 的股票由机构投资者持有。</p>
</div><h2>About Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>关于 Hims &amp; Hers Health</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Hims &amp; Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health, Inc. 运营一个远程医疗咨询平台。它将消费者与医疗专业人员连接，使他们能够获得心理健康、性健康、皮肤病和初级护理的医疗服务。该公司成立于 2017 年，总部位于加利福尼亚州旧金山。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Hims &amp; Hers Health</li>
<li>Special Purpose Acquisition Company (SPAC) What You Need to Know</li>
<li>Is Myers Industries Poised for a Breakout?</li>
<li>Low PE Growth Stocks: Unlocking Investment Opportunities</li>
<li>Is BigBear.ai's 25% Plunge a False Alarm or Fire Sale?</li>
<li>Stock Market Upgrades: What Are They?</li>
<li>Broadcom Confirmed Its AI Outlook: Stock to Hit New Highs Soon</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Hims &amp; Hers Health</li>
<li>特殊目的收购公司 (SPAC) 你需要知道的事项</li>
<li>Myers Industries 是否准备突破？</li>
<li>低市盈率增长股票：解锁投资机会</li>
<li>BigBear.ai 的 25% 暴跌是虚惊一场还是火灾销售？</li>
<li>股票市场升级：它们是什么？</li>
<li>Broadcom 确认其人工智能前景：股票即将创下新高</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Hims &amp; Hers Health 吗？</h2>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Hims &amp; Hers Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Hims &amp; Hers Health 并不在名单上。</p>
</div><p>While Hims &amp; Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Hims &amp; Hers Health 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Hims & Hers Health (NYSE:HIMS) 股价下跌 0.9% - 以下是发生的事情